The EPICAL trial, a phase Ib study combining first line afatinib with anti-EGF vaccination in EGFR-mutant metastatic NSCLC

Autor: Rodríguez-Abreu, D., Cobo, M., García-Román, S., Viteri-Ramírez, S., Jordana-Ariza, N., García-Peláez, B., Reguart, N., Aguilar, A., Codony-Servat, J., Drozdowskyj, A., Molina-Vila, M.A., d'Hondt, E., Rosell, R.

Publikováno v: In Lung Cancer February 2022 164:8-13

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer

Autor: Mayo-de-Las-Casas, C, Ibanez, MG, Jordana-Ariza, N, Garcia-Pelaez, B, Balada-Bel, A, Villatoro, S, Malapelle, U, Karachaliou, N, Troncone, G, Rosell, R, Molina-Vila, MA

Publikováno v: Expert Review of Molecular Diagnostics
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname

Introduction: Collection of tumor samples is not always feasible in non-small cell lung cancer (NSCLC) patients, and circulating free DNA (cfDNA) extracted from blood represents a viable alternative. Different sensitive platforms have been developed

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::976e30d139cbb8caaeb2270fef268d25
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=5819

P59.03 Comparison of Two RNA-Based Platforms for Detection of Fusions and Met Splicing Variant in Non Small Cell Lung Cancer Samples

Autor: García Peláez, B., Gimenez-Capitán, A., Vives Usano, M., Roman, R., Garzón Ibañez, M., Aguado Esteban, C., Rodríguez, S., Aldeguer, E., Jordana Ariza, N., Viteri, S., Aguilar-Hernández, A., Moya, I., Cabrera, C., Catalán, M., Gonzalez-Cao, M., García Román, S., Bertrán- Alamillo, J., Garcia-Casabal, F., Rosell, R., Molina, M., Mayo-De-Las-Casas, C.

Publikováno v: In Journal of Thoracic Oncology October 2021 16(10) Supplement:S1147-S1147

Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial

Autor: Karachaliou N, Mayo-de las Casas C, Queralt C, de Aguirre I, Melloni B, Cardenal F, Garcia-Gomez R, Massuti B, Sánchez JM, Porta R, Ponce-Aix S, Moran T, Carcereny E, Felip E, Bover I, Insa A, Reguart N, Isla D, Vergnenegre A, de Marinis F, Gervais R, Corre R, Paz-Ares L, Morales-Espinosa D, Viteri S, Drozdowskyj A, Jordana-Ariza N, Ramirez-Serrano JL, Molina-Vila MA, Rosell R

Publikováno v: JAMA Oncology
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname

IMPORTANCE: The EURTAC trial demonstrated the greater efficacy of erlotinib compared with chemotherapy for the first-line treatment of European patients with advanced non-small-cell lung cancer (NSCLC) harboring oncogenic epidermal growth factor rece

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::168aa992e8995d3f2629b4103d927817
https://fundanet.isabial.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=8917